VRC MARADC087 00 VP
Alternative Names: cAd3-Marburg vaccine; ChAd3-MARV; VRC-MARADC087-00-VPLatest Information Update: 24 Apr 2025
At a glance
- Originator National Institute of Allergy and Infectious Diseases; ReiThera
- Developer National Institute of Allergy and Infectious Diseases; Sabin Vaccine Institute
- Class Antivirals; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Marburg virus disease
Most Recent Events
- 16 Apr 2025 Phase-II clinical trials in Marburg virus disease (Prevention) in USA (IM) (NCT06620003)
- 19 Dec 2023 Phase-II clinical trials in Marburg virus disease (Prevention) in Kenya (IM) (NCT05817422)
- 19 Oct 2023 Phase-II clinical trials in Marburg virus disease (Prevention) in Uganda (IM) (NCT05817422)